• Who we are
    • ABOUT MEDICINES FOR EUROPE
    • PURPOSE AND OBJECTIVES
    • OUR VALUES – OUR 5 PILLARS
    • STRUCTURE
    • MEMBERS
    • BECOME A MEMBER
    • CODE OF CONDUCT
    • DISCLOSURE
  • Key topics
    • COVID-19
    • ACCESS
    • INDUSTRIAL POLICY
    • REGULATORY AND LEGAL FRAMEWORK
    • FALSIFIED MEDICINES
    • ENVIRONMENT
    • ANTIMICROBIAL RESISTANCE
    • MEDICINE SHORTAGES
  • Publications
    • EXTERNAL RESOURCES
    • FACTSHEETS
    • INFOGRAPHICS
    • PODCAST
    • POLICY
    • REPORTS
    • VIDEOS
  • Newsroom
    • IN THE NEWS
    • PRESS RELEASES
  • Contact us
Login Login
Medicines for Europe
  • Generic medicines
    • Home
    • Medicines for Europe
      • Generic medicines Group
      • MISSION AND VISION
      • STRUCTURE
      • MEMBERS
      • BECOME A MEMBER
    • Did you know?
      • Definition
      • THERAPEUTIC AREAS
      • GLOSSARY
      • Q&A
    • What’s new
      • FACTSHEETS
      • POLICY
      • REPORTS
      • VIDEOS
      • INFOGRAPHICS
    • Our 5 pillars
      • Patients
      • QUALITY
      • VALUE
      • SUSTAINABILITY
      • PARTNERSHIP
    • Find out more
      • Related links
      • Contact us
    • Twitter
  • Biosimilar medicines
    • Home
    • Medicines for Europe
      • Biosimilar medicines Group
      • MISSION AND VISION
      • STRUCTURE
      • MEMBERS
      • BECOME A MEMBER
    • Did you know?
      • DEFINITION
      • THERAPEUTIC AREAS
      • GLOSSARY
      • Q&A
    • What’s new
      • FACTSHEETS
      • POLICY
      • REPORTS
      • VIDEOS
      • INFOGRAPHICS
      • External resources
    • Our 5 pillars
      • Patients
      • QUALITY
      • VALUE
      • SUSTAINABILITY
      • PARTNERSHIP
    • Find out more
      • Related links
      • Contact us
    • Twitter
  • Value added medicines
    • Home
    • Who we are
      • Value added medicines Group
      • MISSION AND VISION
      • STRUCTURE
      • MEMBERS
      • BECOME A MEMBER
    • Did you know?
      • Definition
      • THERAPEUTIC AREAS
      • Q&A
    • What’s new
      • FACTSHEETS
      • POLICY
      • REPORTS
      • VIDEOS
      • INFOGRAPHICS
    • Our 5 pillars
      • Patients
      • QUALITY
      • VALUE
      • SUSTAINABILITY
      • PARTNERSHIP
    • Find out more
      • Contact us
  • Events

Biosimilars in the EU – Information guide for healthcare professionals – now available in 23 languages

29 October 2019
  • Unofficial Ukrainian translation
(PDF/600 KB)

  • English
(PDF/1.85 MB)

  • Bulgarian
(PDF/1.82 MB)

  • Croatian
(PDF/1.81 MB)

  • Czech
(PDF/1.86 MB)

  • Danish

    (PDF/1.84 MB)

  • Dutch

    (PDF/1.83 MB)

  • Estonian

    (PDF/656.54 KB)

  • Finnish

    (PDF/1.79 MB)

  • French

    (PDF/1.86 MB)

  • German

    (PDF/1.9 MB)

  • Greek

    (PDF/1.84 MB)

  • Hungarian

    (PDF/1.86 MB)

  • Italian

    (PDF/1.85 MB)

  • Latvian

    (PDF/1.8 MB)

  • Lithuanian

    (PDF/1.81 MB)

  • Maltese

    (PDF/710.75 KB)

  • Polish

    (PDF/1.87 MB)

  • Portuguese

    (PDF/1.85 MB)

  • Romanian

    (PDF/1.86 MB)

  • Slovak

    (PDF/1.86 MB)

  • Slovenian

    (PDF/1.86 MB)

  • Spanish

    (PDF/1.84 MB)

  • Swedish

    (PDF/1.84 MB)

Related Posts

  • Biosimilars in the EU – Information guide for healthcare… 8 February 2021 Open unofficial Ukrainian translation
  • Заповнення прогалини: Filling the gap - Ukrainian… 17 March 2021 Filling the gap - how off-patent medicines can improve the…
  • Bulgarian National Television - The EU is preparing the most… 4 May 2023 Open
  • Updated Guide to empower nurses managing patients on… 3 October 2022 Nurses in all health domains and specialities play a crucial…
Medicines for Europe
MEMBER OF
IGBA EMVO
  • Contact us
  • Privacy Policy
Medicines for Europe AISBL
Rue d’Arlon 50
1000 Brussels Belgium
T : +32 (0)2 736 84 11
Powered by Big Smile Agency
Medicines For Europe
  • Who we are
  • Key topics
  • Publications
  • Newsroom
  • Contact us
  • SECTOR GROUPS
    • Generic medicines
      • WHO WE ARE
      • DID YOU KNOW?
      • WHAT’S NEW
      • OUR 5 PILLARS
      • FIND OUT MORE
    • Biosimilar medicines
      • WHO WE ARE
      • DID YOU KNOW?
      • WHAT’S NEW
      • OUR 5 PILLARS
      • FIND OUT MORE
    • Value added medicines
      • WHO WE ARE
      • DID YOU KNOW?
      • WHAT’S NEW
      • OUR 5 PILLARS
  • Events
 Tweet
 Tweet
 Tweet
 LinkedIn